Hugin announced that he is pro-choice on abortion and supports same-sex marriage in a campaign ad. He advertised his support for legal abortion and gay marriage. On social issues, Hugin is more socially liberal than most Republicans. Senate seat in New Jersey, Hugin described himself as a "different kind of Republican", "moderate" and "independent". On his 2018 campaign website for the U.S. On November 6, 2018, Hugin was defeated by incumbent Democrat Bob Menendez. President Donald Trump endorsed Hugin via Twitter on Election Day. He defeated Brian Goldberg in the Republican primary that took place on June 5, 2018, by garnering 75% of the vote, to Goldberg's 24%. In the first quarter of 2018, his campaign raised a little under $8 million, of which $7.5 million was a loan from Hugin himself. On February 13, 2018, Hugin announced his candidacy for the U.S. Main article: 2018 United States Senate election in New Jersey He left his position at Celgene as chief executive and became an executive chairman in 2017. In 2013, Hugin was named the best CEO in biotech by. Celgene was able to actively prevent generic versions of the drug from being sold, and by the year 2017, the price for the same amount of Revlimid had been raised by Celgene to over $16,000. For example, in 2006, the drug Revlimid was introduced to the market and cost about $6,000 for a one-month supply. Hugin has been criticized for drastically raising the prices of several drugs while he was in charge of Celgene. In 2017, Celgene was forced to pay $280 million in response to a lawsuit regarding these practices. ĭuring Hugin's tenure, Celgene was reprimanded multiple times by the U.S Food and Drug Administration, including a formal warning letter in 2000 for not sharing all the risks associated with their drugs, and for marketing their drug Thalomid and others to doctors for unapproved uses. In his time at Celgene the market capitalization of the company went from $100 million to $70 billion, and headcount grew to 6,000. In June 2011, he was elected chairman of the Celgene board of directors. Hugin served as Celgene's president and COO since May 2006 and became the CEO of Celgene in June 2010. He was elected to Celgene's board of directors in December 2001. At the time, Celgene had approximately 200 employees and less than six weeks of cash. He joined the company in June 1999 as senior vice president and CFO. Hugin has been credited with saving the biotech corporation Celgene and turning it profitable. Career įrom 1985 to 1999, Hugin worked at J.P. In 2018, he said that his views on these issues had since changed.
#Bob hugin family series#
As president, he opposed the membership of gay men in 1976, stating that a member discovered to be gay "wouldn't last long." Later, as president of the alumni board of Tiger Inn, he led the club's opposition to a 13-year series of lawsuits during the 1980s and 1990s to require the club to admit women, describing the legal campaign to "politically correct fascism”. Īt Princeton, Hugin was president of the male-only Tiger Inn, a highly selective private eating club on campus. In 1985, Hugin earned a master's degree in business administration from the University of Virginia. After graduating, Hugin served in the United States Marine Corps as an active duty infantry officer from 1976 to 1983. He earned a Bachelor of Arts degree from Princeton University in 1976. He was the first in his family to attend college, earning a full-scholarship to Princeton University.
0 kommentar(er)
